Paroxetine in the treatment of generalized social phobia: Open-label treatment and double-blind placebo-controlled discontinuation

Journal of Clinical Psychopharmacology

Volumn 16, Issue 3, 1996, Pages 218-222

  Stein, Murray B ^a,b   Chartier, Mariette J ^a   Hazen, Andrea L ^a   Kroft, Cara D L ^a   Chale, Ron A ^a   Coté, Dennis ^a   Walker, John R ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PAROXETINE; PLACEBO;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DISTRIBUTION; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHOBIA; PRIORITY JOURNAL; PSYCHOTHERAPY; RELAPSE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; PAROXETINE; PHOBIC DISORDERS; TIME FACTORS;

EID: 0030014796     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-199606000-00005     Document Type: Article

References (35)

1. Walker JR, Stein MB. Epidemiology of social phobia In: Stein MB, ed. Social phobia: clinical and research perspectives. Washington, DC: American Psychiatric Press, 1995:43-75.
2. Kessler RG, McGonagle KA, Zhao S, Nelson CB, Hughes M, Eshleman S, Wittchen H-U, Kendler KS. lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
3. Stein MB, Walker JR, Forde DR. Setting diagnostic thresholds for social phobia: considerations from a community survey of social anxiety. Am J Psychiatry 1994;151:408-12.
4. Davidson JRT, Hughes DC, George LK, Blazer DG, The boundary of social phobia: exploring the threshold. Arch Gen Psychiatry 1994;51:975-83.
5. Weiller E, Bisserbe J-C, Boyer P, Lepine J-P, Lecrubier Y. Social phobia in general health care: an unrecognized, undertreated disabling disorder. Br J Psychiatry 1996:168:169-74.
6. Schneier FR, Heckelman LR, Garfinkel R, Campeas R, Fallon BA, Gitow A, Street L, Del Bene D, Liebowitz MR. Functional impairment in social phobia. J Clin Psychiatry 1994;55:322-31.
7. Gelernter CS, Uhde TW, Cimbolic P, Arnkoff DB, Vittone BJ, Tancer ME, Bartko JJ. Cognitive-behavioral and pharmacological treatment of social phobia. Arch Gen Psychiatry 1991;48:938-45.
8. Uebowitz MR, Schneier F, Campeas R, Hollander E, Hatterer J, Fyer A, Gorman J, Papp L, Davies S, Gully R, Klein DF. Phenelzine vs. atenolol in social phobia. Arch Gen Psychiatry 1992;49:290-300.
9. Versiani M, Nardi AE, Mindim FD, Alyes AB, Liebowitz MR, Amrein R. Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 1992;161:353-60.
10. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 1992;2:21-9.
11. Davidson JRT, Potts N, Richichi E, Krishnan R, Ford SM, Smith R, Wilson WH. Treatment of social phobia with clonazepam and placebo. J Clin Psychopharmacol 1993;13:423-8.
12. Nunes EV, McGrath PJ, Quitkin FM. Treating anxiety in patients with alcoholism. J Clin Psychiatry 1995;56[suppl 2]:3-9.
13. Hovens JG, Cantwell DP, Kiriakos R. Psychiatric comorbidity in hospitalized adolescent substance abusers. J Am Acad Child Adolesc Psychiatry 1994;33:476-83.
14. Lotufo-Neto F, Gentil V. Alcoholism and phobic anxiety - a clinical-demographic comparison. Addiction 1994;89:447-53.
15. van Ameringen M, Mancini C, Streiner DL. Fluoxetine efficacy in social phobia. J Clin Psychiatry 1993;54:27-32.
16. Black B, Uhde TW, Tancer ME. Fluoxetine for the treatment of social phobia [letter]. J Clin Psychopharmacol 1992;12:293-5.
17. Schneier FR, Chin SJ, Hollander E, Liebowitz MR. Fluoxetine in social phobia [letter]. J Clin Psychopharmacol 1992;12:62-4.
18. van Ameringen M, Mancini C, Streiner D. Sertraline in social phobia. J Affect Disord 1994;31:141-5.
19. van Vliet IM, den Boer JA, Westenberg HGM. Psychopharmacological treatment of social phobia: A double-blind, placebo-controlled study with fluvoxamine. Psychopharmacology 1994;115:128-34.
20. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline in social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-71.
21. Gelernter CS, Stein MB, Tancer ME, Uhde TW. An examination of syndromal validity and diagnostic subtypes in social phobia and panic disorder. J Clin Psychiatry 1992;53:23-7.
22. Heimberg RG, Hope DA, Dodge CS, Becker RE. DSM-III-R subtypes of social phobia: comparison of generalized social phobics and public-speaking phobes. J Nerv Ment Dis 1990;178:172-9.
23. Heimberg RG, Holt CS, Schneier FR, Spitzer RL, Liebowitz MR. The issue of subtypes in the diagnosis of social phobia. J Anxiety Disord 1993;7:249-69.
24. Mannuzza S, Schneier F, Chapman TF, Liebowitz MR, Klein DF, Fyer AJ. Generalized social phobia: reliability and validity. Arch Gen Psychiatry 1995;52:230-7.
25. Marshall RD, Schneier FR, Fallen BA, Ferick, Liebowitz MR. Medication therapy for social phobia. J Clin Psychiatry 1994;55[suppl 6]:33-7.
26. Pato MT, Zohar-Kadouch R, Zohar J, Murphy DL. Return of symptoms after discontinuation of clomipramine in patients with obsessive-compulsive disorder. Am J Psychiatry 1988;145:1521-5.
27. Klein E, Colin V, Stolk J, Lenox RH. Alprazolam withdrawal in patients with panic disorder and generalized anxiety disorder: vulnerability and effects of carbamazepine. Am J Psychiatry 1994;151:1760-6.
28. Spitzer RL, Williams JBW, Gibbon M, First MB. Structured Clinical Interview for DSM-III-R. Patient ed. Washington, DC: American Psychiatric Press, 1990.
29. Montgomery SA, Smeyatsky N, de Ruiter M, Montgomery DB. Profiles of antidepressant activity with the Montgomery-Asberg Depression Rating Scale. Acta Psychiatr Scand 1985;230[suppl]: 38-42.
30. Liebowitz MR. Social phobia Mod Probl Pharmacopsychiatry 1987;22:141-73.
31. Davidson JRT, Potts NLS, Richichi EA, Ford SM, Krishnan KR, Smith RD, Wilson W. The Brief Social Phobia Scale. J Clin Psychiatry 1991;52[suppl 11]:48-51.
32. Watson D, Friend R. Measurement of social-evaluative anxiety. J Consult Clin Psychol 1969;33:448-57.
33. Mattick RP, Peters L, Clarke JC. Exposure and cognitive restructuring for social phobia: a controlled study. Behav Ther 1989;20:3-23.
34. Leon AC, Shear MK, Portera L, Klerman GL. Assessing impair ment in patients with panic disorder: the Sheehan Disability Scale. Soc Psychiatry Psychiatr Epidemiol 1992;27:78-82.
35. Otto MW, Pollack MH, Sachs GS, Reiter SR, Meltzer-Brody S, Rosenbaum JF. Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 1993;150:1485-90.